Your best medicine news resource
Oct 3rd 2008Drug InformationClinical Trials
Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, announced the initiation of its first clinical trial with OREX-003, a proprietary sustained release formulation of zonisamide plus olanzapine.
More: continued here
Oct 3rd 2008Drug InformationClinical Trials
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. Now, maraviroc, the first of a new class of HIV drugs called CCR5 receptor antagonists, has been shown to be effective over 48 weeks for drug-resistant patients with R5 HIV-1, a variation of the virus found in more than half of HIV-infected patients.
More: continued here
Oct 3rd 2008Drug InformationClinical Trials
Drug delivery company, pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FF: PV3), together with its licensing and development partner, Alimera Sciences, have today reported the interim six-month safety and efficacy results from the first human pharmacokinetici (PK) study of Medidur? FA, which will be marketed under the trade name Iluvien?, if approved by the U.S. Food and Drug Administration.
More: continued here
Oct 3rd 2008Drug InformationClinical Trials
STAYING SHARP IN CONCORD: LEADING BRAIN EXPERTS DISCUSS SUCCESSFUL AGING WHAT: Brain function and health will be the focus of the Staying Sharp session on October 4 at the Embassy Suites Hotel Resort and Conference Center in Concord, NC.
More: continued here
Oct 3rd 2008Drug InformationClinical Trials
Calabar AB announced that their Phase II repeated dose study in xerostomia (”dry mouth”) patients has been initiated. Specifically, the drug will be studied in 45 dry mouth patients between the ages of 20 to 75. The objective of the study is to select a dose for evaluation in a succeeding Phase III efficacy study. Xalieve(TM) is a gel containing the cholinesterase inhibitor physostigmine.
More: continued here
Oct 3rd 2008Drug InformationClinical Trials
Researchers at NorthShore University HealthSystem (NorthShore) and Northwestern University have discovered that fiber optic technology can for the very first time effectively measure blood levels in the colonic lining (mucosa) in humans, thus having potential applications for analyzing risk of colon cancer. The study appears in the October 2008 issue of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
More: continued here
Oct 3rd 2008Drug InformationClinical Trials
In pre-clinical studies, vitamin C appears to substantially reduce the effectiveness of anticancer drugs, say researchers at Memorial Sloan-Kettering Cancer Center.
More: continued here
Oct 3rd 2008Drug InformationClinical Trials
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, reported the interim month six safety and efficacy results from the first human pharmacokinetic (PK) study of Iluvien(TM). Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME).
More: continued here
Oct 3rd 2008Drug InformationClinical Trials
Thrombolytic treatment with Actilyse (alteplase; Boehringer Ingelheim) significantly reduces the risk of patients with mild to moderate stroke being left with any residual disability when given within 4.5 hours of symptom onset - extending the time for administration beyond the currently licensed three hours - according to a major study reported at the recent
More: continued here
Oct 3rd 2008Drug InformationClinical Trials
Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetic market, today announced completion of the first of three Phase 3 clinical trials with its purified botulinum Type A neurotoxin (PurTox®) for the reduction of glabellar rhytides (frown lines). This newly completed study involved 400 subjects at ten investigational sites in the United States. Subjects received a single treatment with PurTox or placebo.
More: continued here
Your best medicine news resource
